• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    12/14/22 8:06:56 AM ET
    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email

    Gainers

    • Vallon Pharmaceuticals (NASDAQ:VLON) shares increased by 232.7% to $0.84 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million.
    • Immix Biopharma (NASDAQ:IMMX) stock moved upwards by 45.2% to $2.12. The market value of their outstanding shares is at $29.5 million.
    • Avidity Biosciences (NASDAQ:RNA) stock increased by 34.79% to $14.8. The company's market cap stands at $806.0 million.
    • Kymera Therapeutics (NASDAQ:KYMR) shares moved upwards by 32.95% to $34.37. The market value of their outstanding shares is at $1.8 billion.
    • Fortress Biotech (NASDAQ:FBIO) stock moved upwards by 23.34% to $0.81. The market value of their outstanding shares is at $87.9 million.
    • Passage Bio (NASDAQ:PASG) shares moved upwards by 16.32% to $1.33. The company's market cap stands at $72.3 million.

    Losers

    • Yumanity Therapeutics (NASDAQ:YMTX) stock decreased by 18.7% to $1.65 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.9 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) stock fell 18.56% to $1.8. The market value of their outstanding shares is at $29.1 million. As per the press release, Q4 earnings came out yesterday.
    • BeyondSpring (NASDAQ:BYSI) stock fell 17.48% to $0.85. The market value of their outstanding shares is at $33.0 million.
    • Healthcare Triangle (NASDAQ:HCTI) shares fell 12.65% to $0.21. The market value of their outstanding shares is at $8.7 million.
    • Vincerx Pharma (NASDAQ:VINC) stock decreased by 10.44% to $0.97. The market value of their outstanding shares is at $20.4 million.
    • OpGen (NASDAQ:OPGN) shares fell 9.53% to $0.21. The market value of their outstanding shares is at $11.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BYSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BYSI
    $FBIO
    $HCTI
    $IMMX

    CompanyDatePrice TargetRatingAnalyst
    Kymera Therapeutics Inc.
    $KYMR
    3/16/2026Buy
    Jefferies
    Atrium Therapeutics Inc.
    $RNA
    3/11/2026$25.00Overweight
    Wells Fargo
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    Kymera Therapeutics Inc.
    $KYMR
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Kymera Therapeutics Inc.
    $KYMR
    11/3/2025$90.00Buy
    Guggenheim
    More analyst ratings

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Director Baker Bros. Advisors Lp bought $172,499,918 worth of shares (2,005,813 units at $86.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    12/11/25 4:19:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:49:30 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Borthwick Kathleen

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    3/18/26 4:07:20 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chou William

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    3/18/26 4:06:33 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Business Development Director Christianson Mark sold $734 worth of shares (917 units at $0.80), decreasing direct ownership by 0.43% to 214,283 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/16/26 3:30:00 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    SEC Filings

    View All

    Jefferies resumed coverage on Kymera Therapeutics

    Jefferies resumed coverage of Kymera Therapeutics with a rating of Buy

    3/16/26 9:35:47 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

    Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

    3/11/26 8:36:38 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan

    PLEASANTON, Calif., March 11, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announces that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2,000,000 of its outstanding common stock ("2026 Share Repurchase Plan"). The 2026 Share Repurchase Plan was approved by the Company's Board of Directors on March 9, 2026, and became effective immediately. Under the newly authorized plan, the Company may repurchase shares of its common stock from tim

    3/11/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

    WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. Kymera will also host a booth (#3551) in the congress exhibit hall. "We are honored to have our KT-621 BroADen Phase 1b data selected for a late-breaking oral presentation at AAD," sai

    3/10/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Kymera Therapeutics Inc.

    144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

    3/11/26 4:40:00 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Healthcare Triangle Inc.

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    3/11/26 4:30:29 PM ET
    $HCTI
    EDP Services
    Technology

    Passage Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Passage BIO, Inc. (0001787297) (Filer)

    3/10/26 7:15:33 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Next-Generation Platforms Scale Across Energy, Wellness, and Smokeless Consumer Segments

    Issued on behalf of Doseology Sciences Inc.Equity-Insider.com VANCOUVER, BC, March 5, 2026 /CNW/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients[1]. The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing[1]. This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sc

    3/5/26 9:00:00 AM ET
    $HLF
    $NHTC
    $NMTC
    Other Pharmaceuticals
    Health Care
    Consumer Specialties
    Consumer Discretionary

    Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral

    2/26/26 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Leadership Updates

    Live Leadership Updates

    View All

    Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera's legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and oth

    9/3/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $BYSI
    $FBIO
    $HCTI
    $IMMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care